Janus Henderson Group’s Viridian Therapeutics VRDN Stock Holding History

Janus Henderson Group’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$537K	Hold	27,472	–	–	﹤0.01%	1981
2025 Q4	$854K	Hold	27,472	–	–	﹤0.01%	1753
2025 Q3	$593K	Hold	27,472	–	–	﹤0.01%	1925
2025 Q2	$384K	Hold	27,472	–	–	﹤0.01%	2075
2025 Q1	$397K	Hold	27,472	–	–	﹤0.01%	2076
2024 Q4	$526K	Hold	27,472	–	–	﹤0.01%	2006
2024 Q3	$625K	Hold	27,472	–	–	﹤0.01%	1924
2024 Q2	$357K	Buy	27,472 +14,051	+105%	+$195K	﹤0.01%	2126
2024 Q1	$235K	Buy	13,421 +57	+0.4%	+$1.1K	﹤0.01%	2344
2023 Q4	$291K	Sell	13,364 -31	-0.2%	-$489	﹤0.01%	2249
2023 Q3	$206K	Buy	13,395 +9	+0.1%	+$172	﹤0.01%	2371
2023 Q2	$318K	Sell	13,386 -28	-0.2%	-$718	﹤0.01%	2218
2023 Q1	$341K	Buy	+13,414	New	+$430K	﹤0.01%	2222

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group's VRDN Position: Q1 2026 in Review

Janus Henderson Group held its Viridian Therapeutics (VRDN) position steady in Q1 2026 at 27,472 shares worth $537K. The position accounts for ﹤0.01% of the portfolio, ranked #1981.

Janus Henderson Group first reported a position in VRDN in Q1 2023 and has held it in 13 quarters since. The position peaked at $854K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

Janus Henderson Group held 27,472 shares of Viridian Therapeutics worth $537K as of Q1 2026.
Janus Henderson Group left its Viridian Therapeutics share count unchanged in Q1 2026.
Viridian Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1981 holding.
Janus Henderson Group first reported a position in Viridian Therapeutics in Q1 2023 and has held it in 13 quarters since.
Janus Henderson Group's Viridian Therapeutics position peaked at $854K in Q4 2025.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.